Inhibition of mast cell‐secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2−/− mice

Hannah Jones, Laura Hargrove, Lindsey Kennedy, Fanyin Meng, Allyson Graf‐Eaton, Jennifer Owens, Gianfranco Alpini, Christopher Johnson, Francesca Bernuzzi, Jennifer Demieville, Sharon DeMorrow, Pietro Invernizzi, Heather Francis – 28 June 2016 – Hepatic fibrosis is marked by activation of hepatic stellate cells (HSCs). Cholestatic injury precedes liver fibrosis, and cholangiocytes interact with HSCs promoting fibrosis. Mast cells (MCs) infiltrate following liver injury and release histamine, increasing biliary proliferation.

G‐protein‐coupled bile acid receptor plays a key role in bile acid metabolism and fasting‐induced hepatic steatosis in mice

Ajay C. Donepudi, Shannon Boehme, Feng Li, John Y.L. Chiang – 28 June 2016 – Bile acids are signaling molecules that play a critical role in regulation of hepatic metabolic homeostasis by activating nuclear farnesoid X receptor (Fxr) and membrane G‐protein‐coupled receptor (Takeda G‐protein‐coupled receptor 5; Tgr5). The role of FXR in regulation of bile acid synthesis and hepatic metabolism has been studied extensively. However, the role of TGR5 in hepatic metabolism has not been explored.

Sofosbuvir‐based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation

Jérôme Dumortier, Vincent Leroy, Christophe Duvoux, Victor de Ledinghen, Claire Francoz, Pauline Houssel‐Debry, Sylvie Radenne, Louis d'Alteroche, Claire Fougerou‐Leurent, Valérie Canva, Vincent di Martino, Filomena Conti, Nassim Kamar, Christophe Moreno, Pascal Lebray, Albert Tran, Camille Besch, Alpha Diallo, Alexandra Rohel, Emilie Rossignol, Armand Abergel, Danielle Botta‐Fridlund, Audrey Coilly, Didier Samuel, Jean‐Charles Duclos‐Vallée, Georges‐Philippe Pageaux – 27 June 2016 – Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrh

Lower rates of receiving model for end‐stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma

Kellie Young, Maria Aguilar, Robert Gish, Zobair Younossi, Sammy Saab, Taft Bhuket, Benny Liu, Aijaz Ahmed, Robert J. Wong – 27 June 2016 – Receiving Model for End‐Stage Liver Disease (MELD) exception status for hepatocellular carcinoma (HCC) improves wait‐list survival and probability of liver transplantation (LT). We aim to evaluate etiology‐specific disparities in MELD exception, LT wait‐list times, and post‐LT outcomes among patients with HCC listed for LT.

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)

Nathalie Ganne‐Carrié, Richard Layese, Valérie Bourcier, Carole Cagnot, Patrick Marcellin, Dominique Guyader, Stanislas Pol, Dominique Larrey, Victor Lédinghen, Denis Ouzan, Fabien Zoulim, Dominique Roulot, Albert Tran, Jean‐Pierre Bronowicki, Jean‐Pierre Zarski, Ghassan Riachi, Paul Calès, Jean‐Marie Péron, Laurent Alric, Marc Bourlière, Philippe Mathurin, Jean‐Frédéric Blanc, Armand Abergel, Lawrence Serfaty, Ariane Mallat, Jean‐Didier Grangé, Pierre Attali, Yannick Bacq, Claire Wartelle, Thông Dao, Yves Benhamou, Christophe Pilette, Christine Silvain, Christos Christidis, Dominique Capro

Subscribe to